Amoy Diagnostics Co Ltd (300685) - Total Liabilities
Based on the latest financial reports, Amoy Diagnostics Co Ltd (300685) has total liabilities worth CN¥272.62 Million CNY (≈ $39.89 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amoy Diagnostics Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Amoy Diagnostics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Amoy Diagnostics Co Ltd (300685) asset resilience to evaluate the company's liquid asset resilience ratio.
Amoy Diagnostics Co Ltd Competitors by Total Liabilities
The table below lists competitors of Amoy Diagnostics Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wenzhou Hongfeng Electrical Alloy Co Ltd
SHE:300283
|
China | CN¥2.38 Billion |
|
Luye Pharma Group Ltd
F:LUP
|
Germany | €14.47 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥271.65 Million |
|
Shanghai Yct Electronics Group Co.Ltd
SHE:301099
|
China | CN¥2.54 Billion |
|
Inversiones Aguas Metropolitanas SA
SN:IAM
|
Chile | CL$1.80 Trillion |
|
Guardian Capital Group Ltd. Cl.A Nv (GCG-A.TO
TO:GCG-A
|
Canada | CA$748.64 Million |
|
O-I Glass Inc
NYSE:OI
|
USA | $7.52 Billion |
|
XPLR Infrastructure LP Unit
NYSE:XIFR
|
USA | $8.78 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Amoy Diagnostics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Amoy Diagnostics Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amoy Diagnostics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amoy Diagnostics Co Ltd (2012–2024)
The table below shows the annual total liabilities of Amoy Diagnostics Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥221.54 Million ≈ $32.42 Million |
-4.33% |
| 2023-12-31 | CN¥231.56 Million ≈ $33.88 Million |
+53.15% |
| 2022-12-31 | CN¥151.20 Million ≈ $22.12 Million |
+0.63% |
| 2021-12-31 | CN¥150.25 Million ≈ $21.99 Million |
-8.61% |
| 2020-12-31 | CN¥164.41 Million ≈ $24.06 Million |
+13.64% |
| 2019-12-31 | CN¥144.67 Million ≈ $21.17 Million |
+133.31% |
| 2018-12-31 | CN¥62.01 Million ≈ $9.07 Million |
+35.84% |
| 2017-12-31 | CN¥45.65 Million ≈ $6.68 Million |
+0.55% |
| 2016-12-31 | CN¥45.39 Million ≈ $6.64 Million |
-16.78% |
| 2015-12-31 | CN¥54.55 Million ≈ $7.98 Million |
-38.65% |
| 2014-12-31 | CN¥88.90 Million ≈ $13.01 Million |
+25.13% |
| 2013-12-31 | CN¥71.05 Million ≈ $10.40 Million |
+43.24% |
| 2012-12-31 | CN¥49.60 Million ≈ $7.26 Million |
-- |
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more